Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Apr 10, 2013 at 10:35 AM EDT

More Worries About Boston Scientific Turnaround Story

Thinkstock24/7 Wall St. recently featured the waves of the most promising turnarounds for 2013. It was amazing to see some…

Jon C. Ogg | Apr 5, 2013 at 8:15 AM EDT

Top Analyst Upgrades and Downgrades (CELG, CMCSA, FB, FFIV, JPM, JNPR, KMB, NWSA, PDCE, AET, CI, HUM, UNH, WLP)

Jon OggInvestors and traders are usually on the hunt for new ideas that will generate positive returns or income. 24/7…

Douglas A. McIntyre | Apr 4, 2013 at 7:05 AM EDT

How the U.S. Is Making the Rest of the World Fat

ThinkstockPeople who live in nations where most residents were thin, at least as measured against the tremendous number of obese…

Jon C. Ogg | Apr 3, 2013 at 9:20 AM EDT

Boston Scientific Downgrade — Valuation or Turnaround Risk?

Boston Scientific Corp. (NYSE: BSX) is in a long-term turnaround that frankly just feels like it never really has turned…

Jon C. Ogg | Mar 28, 2013 at 8:50 AM EDT

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

ThinkstockMuch of the research coverage on Wall St. from the bulge bracket firms is concentrated on the most liquid, best…

Jon C. Ogg | Mar 27, 2013 at 4:16 PM EDT

Another Major MS Approval Keeps Driving Biogen Idec

ThinkstockShares of Biogen Idec Inc. (NASDAQ: BIIB) did not just do well on Wednesday. The stock hit an all-time high.…

Jon C. Ogg | Mar 27, 2013 at 12:05 PM EDT

Aastrom Implosion Could Have Been Even Worse

ThinkstockAastrom Biosciences Inc. (NASDAQ: ASTM) has just joined in on the long list of biotech implosions. Perhaps the only thing…

Jon C. Ogg | Mar 27, 2013 at 10:50 AM EDT

Chelsea Therapeutics Rally — Speculation or Desperation?

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is rallying on Wednesday after a report in Seeking Alpha called its Northera, a treatment for…

Jon C. Ogg | Mar 27, 2013 at 8:50 AM EDT

Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC)

ThinkstockAccording to the Center for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are…

Jon C. Ogg | Mar 26, 2013 at 7:35 AM EDT

ZIOPHARM Joins Biotech Implosion Watch After Sarcoma Failure

ThinkstockZIOPHARM Oncology Inc. (NASDAQ: ZIOP) is on implosion watch. The small-cap biotech is indicated to be way down on a…

Jon C. Ogg | Mar 25, 2013 at 10:50 AM EDT

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

ThinkstockSarepta Therapeutics Inc. (NASDAQ: SRPT) should have received a huge boost from “The Barron’s Effect” on Monday. The financial publication,…

Jon C. Ogg | Mar 20, 2013 at 9:00 AM EDT

Model N Sets Up for Strong IPO Debut

ThinkstockInvestors always seem to be on the lookout for initial public offerings. The newest IPO coming to market is Model…

Paul Ausick | Mar 19, 2013 at 8:30 AM EDT

Affymax Stares into the Face of Oblivion

ThinkstockAfter the markets closed last night, drugmaker Affymax Inc. (NASDAQ: AFFY) said that it would cut 230 workers (75% of…

Jon C. Ogg | Mar 11, 2013 at 9:20 AM EDT

Omthera Pharmaceuticals Files for IPO

ThinkstockOmthera Pharmaceuticals has joined the wave of companies wanting to come public. Omthera is a clinical stage biotech and will…

Jon C. Ogg | Mar 8, 2013 at 9:00 AM EST

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

ThinkstockPharmacyclics Inc. (NASDAQ: PCYC) has had a monster stock performance, with gains of much more than 200% over the past…

1 … 305 306 307 308 309 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

More Worries About Boston Scientific Turnaround Story

Top Analyst Upgrades and Downgrades (CELG, CMCSA, FB, FFIV, JPM, JNPR, KMB, NWSA, PDCE, AET, CI, HUM, UNH, WLP)

How the U.S. Is Making the Rest of the World Fat

Boston Scientific Downgrade — Valuation or Turnaround Risk?

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

Another Major MS Approval Keeps Driving Biogen Idec

Aastrom Implosion Could Have Been Even Worse

Chelsea Therapeutics Rally — Speculation or Desperation?

Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC)

ZIOPHARM Joins Biotech Implosion Watch After Sarcoma Failure

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

Model N Sets Up for Strong IPO Debut

Affymax Stares into the Face of Oblivion

Omthera Pharmaceuticals Files for IPO

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

3 Dividend Stocks Built for Retirement to Buy in June

From PC Maker to AI Giant: How Dell Rewarded Patient Investors With Nearly 1,900% Gains and AI Capex Determines The Future

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

3 Dividend Stocks Built for Retirement to Buy in June

From PC Maker to AI Giant: How Dell Rewarded Patient Investors With Nearly 1,900% Gains and AI Capex Determines The Future

Health and Healthcare Articles

All Health and Healthcare Articles

More Worries About Boston Scientific Turnaround Story

Top Analyst Upgrades and Downgrades (CELG, CMCSA, FB, FFIV, JPM, JNPR, KMB, NWSA, PDCE, AET, CI, HUM, UNH, WLP)

How the U.S. Is Making the Rest of the World Fat

Boston Scientific Downgrade — Valuation or Turnaround Risk?

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

Another Major MS Approval Keeps Driving Biogen Idec

Aastrom Implosion Could Have Been Even Worse

Chelsea Therapeutics Rally — Speculation or Desperation?

Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC)

ZIOPHARM Joins Biotech Implosion Watch After Sarcoma Failure

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

Model N Sets Up for Strong IPO Debut

Affymax Stares into the Face of Oblivion

Omthera Pharmaceuticals Files for IPO

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

3 Dividend Stocks Built for Retirement to Buy in June

From PC Maker to AI Giant: How Dell Rewarded Patient Investors With Nearly 1,900% Gains and AI Capex Determines The Future

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation